| P2093 | author name string | Fawzia Bardag-Gorce | |
| P2860 | cites work | Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial | Q28139961 |
| | Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients | Q28267360 |
| | The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor? | Q28285160 |
| | Chronic ethanol feeding affects proteasome-interacting proteins | Q28582843 |
| | Superoxide anions and hydrogen peroxide induce hepatocyte death by different mechanisms: involvement of JNK and ERK MAP kinases | Q46822908 |
| | A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. | Q51751998 |
| | Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells. | Q52932265 |
| | p-hydroxyphenylacetaldehyde, an aldehyde generated by myeloperoxidase, modifies phospholipid amino groups of low density lipoprotein in human atherosclerotic intima | Q73615725 |
| | Glutathione: an overview of biosynthesis and modulation | Q74811856 |
| | Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease | Q79422098 |
| | Intragastric ethanol infusion model for cellular and molecular studies of alcoholic liver disease | Q31927611 |
| | Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors | Q33151848 |
| | Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells | Q33262643 |
| | Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis | Q33264524 |
| | A phase 2 study of bortezomib in relapsed, refractory myeloma | Q33348702 |
| | Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study | Q33358394 |
| | Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma | Q33364240 |
| | Targeting the UPS as therapy in multiple myeloma | Q33384287 |
| | Disulfiram treatment of alcoholism | Q34213641 |
| | Novel roles for glutathione in gene expression, cell death, and membrane transport of organic solutes | Q34307424 |
| | Proteasome inhibitor up regulates liver antioxidative enzymes in rat model of alcoholic liver disease | Q34514734 |
| | Free radicals in alcoholic myopathy: indices of damage and preventive studies. | Q34591041 |
| | Effects of alcohol and oxidative stress on liver pathology: the role of the mitochondrion | Q34689211 |
| | Strategies for reversing drug resistance | Q35567287 |
| | Chronic ethanol feeding increases activation of NADPH oxidase by lipopolysaccharide in rat Kupffer cells: role of increased reactive oxygen in LPS-stimulated ERK1/2 activation and TNF-alpha production | Q35962815 |
| | The proteasome and MHC class I antigen processing | Q35967572 |
| | Regulation of ubiquitin-proteasome system mediated degradation by cytosolic stress | Q36095718 |
| | Neuroprotection with the proteasome inhibitor MLN519 in focal ischemic brain injury: relation to nuclear factor kappaB (NF-kappaB), inflammatory gene expression, and leukocyte infiltration | Q36499413 |
| | Proteasome inhibitors: antitumor effects and beyond | Q36649676 |
| | Alcohol-induced oxidative stress. | Q36849866 |
| | Role of the proteasome in ethanol-induced liver pathology | Q36924353 |
| | A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis | Q37091511 |
| | Quantifying the risk for alcohol-use and alcohol-attributable health disorders: present findings and future research needs | Q37108851 |
| | Epigenetics of proteasome inhibition in the liver of rats fed ethanol chronically | Q37122582 |
| | Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity? | Q37347218 |
| | The persisting challenge of selective and specific proteasome inhibition | Q37358550 |
| | Intracellular distribution of oxidized proteins and proteasome in HT22 cells during oxidative stress. | Q40288929 |
| | Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species | Q40757681 |
| | GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect. | Q41558522 |
| | Inhibition of ethanol-induced liver disease in the intragastric feeding rat model by chlormethiazole | Q41758278 |
| | Bortezomib (millennium pharmaceuticals). | Q44475598 |
| | A randomized placebo controlled trial of vitamin E for alcoholic hepatitis | Q44691206 |
| | Proteasome inhibition induces cytokeratin accumulation in vivo | Q44792746 |
| | A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis | Q44880279 |
| | Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer | Q44915315 |
| | Phase II trial of bortezomib for patients with advanced renal cell carcinoma | Q45057193 |
| | Marked differences in the efficacy of post-insult gene therapy with catalase versus glutathione peroxidase | Q45888141 |
| | The effect of ethanol-induced cytochrome p4502E1 on the inhibition of proteasome activity by alcohol. | Q46010291 |
| | Proteasome inhibition prevents experimentally-induced endothelial dysfunction. | Q46028219 |
| | Diallyl trisulfide (DATS) effectively attenuated oxidative stress-mediated liver injury and hepatic mitochondrial dysfunction in acute ethanol-exposed mice | Q46405460 |
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2558-2562 | |
| P577 | publication date | 2011-05-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Proteasome inhibitor treatment in alcoholic liver disease | |
| P478 | volume | 17 | |